Equities

AngioDynamics Inc

AngioDynamics Inc

Actions
  • Price (USD)5.82
  • Today's Change0.035 / 0.61%
  • Shares traded244.69k
  • 1 Year change-29.86%
  • Beta0.6737
Data delayed at least 15 minutes, as of Apr 26 2024 20:24 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

AngioDynamics, Inc. is a transformative medical technology company. The Company is focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving quality of life for patients. It designs, manufactures, and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Its devices are generally used in minimally invasive, image-guided procedures. Its segments include Med Tech and Med Device. Its product categories include oncology, venous therapies, vascular interventions, and ports. Its oncology products include Model 1500X RF Generator, IsoLoc Endorectal Balloon, Habib 4X Laparoscopic Bipolar Resection Device, Habib 4X Bipolar Resection Device, and Alatus. Its venous therapies include VenaCure EVLT 1470 Pro Laser, VenaCure EVLT System, VenaCure EVLT Procedure Packs, and others.

  • Revenue in USD (TTM)324.01m
  • Net income in USD-192.37m
  • Incorporated1992
  • Employees815.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Inogen Inc315.66m-102.45m152.58m834.00--0.738--0.4834-4.42-4.4213.628.780.86346.766.01378,489.20-28.02-8.23-34.53-9.5340.1444.54-32.46-10.312.56--0.00---16.32-2.49-22.30--26.34--
Orchestra Biomed Holdings Inc2.76m-49.12m158.85m56.00--2.33--57.55-1.49-1.490.08321.900.02890.881528.3149,285.71-51.49---61.01--93.26---1,779.71--7.94--0.00---21.88---37.91------
InfuSystem Holdings Inc125.79m872.00k161.82m499.00192.033.0812.051.290.03960.03965.862.471.2411.176.85252,074.100.86214.601.015.6950.1756.430.69334.071.541.880.35750.0014.4413.384,744.44--6.01--
Semler Scientific Inc68.18m20.58m182.18m92.009.862.488.602.672.632.638.7110.430.968815.2813.62741,130.4029.2538.8332.2444.4189.7690.2230.1932.5810.56--0.00--20.2825.9843.6932.64-0.3821--
Akoya Biosciences Inc96.63m-63.32m187.72m330.00--3.49--1.94-1.48-1.482.181.090.54232.497.23292,827.30-35.53---44.59--58.27---65.53--2.94-10.940.5882--29.09--10.36------
Stereotaxis Inc26.77m-22.06m193.00m122.00--11.64--7.21-0.2737-0.27370.33180.27080.56171.466.01219,434.40-43.46-25.02-61.11-34.1255.5167.57-77.37-41.901.88--0.00---4.89-1.82-12.33--6.63--
Accuray Inc447.48m-14.55m216.19m1.02k--4.54--0.4831-0.1496-0.14964.620.48060.94691.905.37436,994.20-3.08-1.45-5.28-2.4833.9737.86-3.25-1.620.84060.32620.7857--4.122.03-73.56--13.92--
Senseonics Holdings Inc22.39m-60.39m221.99m132.00--6.20--9.91-0.1023-0.10230.03870.13850.14182.406.41169,621.20-38.24-73.65-45.21-106.9713.81-40.41-269.73-649.867.03--0.3593--36.623.43-142.49---18.76--
AngioDynamics, Inc.324.01m-192.37m231.52m815.00--1.07--0.7145-4.78-4.788.105.410.74682.666.46397,555.80-44.34-9.12-54.02-10.1750.1754.23-59.37-19.481.62--0.00--7.135.30-97.54--3.55--
Utah Medical Products, Inc.50.22m16.64m237.92m169.0014.491.8810.374.744.574.5713.8135.350.38732.1911.25297,183.4012.8312.6913.3813.1959.8161.5733.1230.5120.53--0.0037.05-3.933.640.98341.659.711.86
Sight Sciences Inc81.06m-55.55m254.70m214.00--2.10--3.14-1.14-1.141.672.450.42691.705.51378,761.70-29.26-38.78-31.77-42.2085.3480.74-68.53-105.1412.65-10.590.2201--13.6360.8435.59--6.77--
Edap Tms SA (ADR)64.83m-22.72m275.39m307.00--4.51--4.25-0.6143-0.61431.751.650.62722.683.86211,166.30-21.98-6.62-29.54-9.2240.4043.23-35.05-9.592.30-27.440.1045--9.649.05-622.06--32.75--
Pulmonx Corp68.68m-60.84m283.33m279.00--2.38--4.13-1.60-1.601.813.070.36981.146.61246,147.00-32.76-26.27-36.90-28.9773.9071.95-88.60-93.765.77--0.2394--27.9827.98-3.26--20.62--
AxoGen Inc159.01m-21.72m284.95m426.00--2.94--1.79-0.5070-0.50703.712.220.81081.636.72373,267.60-11.07-13.92-12.85-15.8478.4679.74-13.66-20.282.14--0.3277--14.7413.6324.98--17.70--
CVRx Inc39.30m-41.20m310.76m200.00--3.96--7.91-1.99-1.991.893.640.32720.69746.02196,475.00-34.31---36.75--84.08---104.85--12.86-23.960.2779--74.89--0.5528------
Data as of Apr 26 2024. Currency figures normalised to AngioDynamics Inc's reporting currency: US Dollar USD

Institutional shareholders

42.23%Per cent of shares held by top holders
HolderShares% Held
BlackRock Fund Advisorsas of 31 Dec 20233.66m9.18%
The Vanguard Group, Inc.as of 31 Dec 20232.24m5.61%
Systematic Financial Management LPas of 31 Dec 20231.93m4.85%
Millennium Management LLCas of 31 Dec 20231.84m4.61%
Morgan Stanley & Co. LLCas of 31 Dec 20231.82m4.56%
Dimensional Fund Advisors LPas of 31 Dec 20231.49m3.74%
Assenagon Asset Management SA (Germany)as of 31 Dec 20231.05m2.65%
SSgA Funds Management, Inc.as of 31 Dec 20231.01m2.53%
Acadian Asset Management LLCas of 31 Dec 2023904.42k2.27%
Geode Capital Management LLCas of 31 Dec 2023896.81k2.25%
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.